Blake Wise

Blake Wise is CEO at Novome Biotechnologies, a biotechnology company focused on engineering defined activities into bacteria of the human gut microbiota to treat chronic diseases. Prior to Novome, Mr. Wise served as CEO of Achaogen, and previously as President and COO, where he oversaw the development and FDA approval of ZEMDRI (plazomicin) for adults with complicated urinary tract infections. Prior to joining Achaogen, Mr. Wise spent 13 years at Genentech in multiple leadership positions of increasing responsibility, including Vice President in Genentech’s BioOncology business unit. Prior to joining Genentech, Mr. Wise worked in consumer marketing, e-commerce and online marketing in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.